ADMA Biologics Launches \$125 Million Accelerated Share Repurchase; Targets \$200 Million Capital Return in 2026

RAMSEY, N.J. and BOCA RATON, Fla., March 2, 2026 – ADMA Biologics, Inc. (Nasdaq: ADMA), a U.S.-based, fully integrated commercial biopharmaceutical company, announced a significant capital return initiative for 2026, aiming to return approximately \$200 million to shareholders. This includes the execution of a \$125 million Accelerated Share Repurchase (ASR) agreement with JPMorgan Chase Bank, National Association. The initiative demonstrates ADMA’s confidence in its financial strength, sustainable free cash flow, and long-term growth prospects.

Key Points of the Announcement

• \$125 Million ASR Agreement: ADMA will pay JPMorgan an upfront amount of \$125 million. In return, ADMA will immediately receive approximately 6.4 million shares of its common stock (about 80% of the shares expected to be repurchased under the ASR), based on the closing price of \$15.57 per share as of February 27, 2026.
• Final Settlement Terms: The total shares repurchased will be based on the average daily volume-weighted average price (VWAP) of ADMA’s common stock over the ASR term, less an agreed discount. The transaction is expected to complete within the next five months. Depending on the final VWAP, ADMA may receive additional shares, or in rare circumstances, need to deliver shares or make a cash payment to JPMorgan.
• Expanded Share Repurchase Program: The ASR is part of ADMA’s \$500 million authorized share repurchase program. Since its authorization in May 2025, ADMA will have repurchased approximately \$160 million of its common stock, including the ASR. The company plans to be opportunistic with further buybacks, potentially executing additional repurchases under Rule 10b5-1 trading plans or in open market transactions throughout 2026, subject to market conditions and other factors.
• Management’s Rationale: CEO Adam Grossman stated that ADMA considers its common stock to be a highly attractive near-term capital deployment opportunity, emphasizing the company’s continued revenue growth, expanding margins, and anticipated acceleration in cash flow generation. Management believes the stock is undervalued relative to the company’s fundamentals and that this buyback enhances long-term shareholder value.

Shareholder-Relevant and Price-Sensitive Information

• Size and Acceleration of Buybacks: The \$125 million ASR is a significant and immediate deployment of capital, likely to reduce the number of shares outstanding and potentially boost earnings per share (EPS).
• Long-Term Capital Return Target: The company has set a clear target of returning \$200 million to shareholders in 2026, demonstrating strong confidence in its cash generation and growth prospects.
• Stock Valuation Comment: Management’s statements that the stock is “meaningfully undervalued” could be interpreted as a strong signal to market participants about insider confidence in future performance.
• Ongoing Flexibility: The company retains the ability to buy back up to \$500 million in shares under its program, indicating further potential for capital return if conditions are favorable.

About ADMA Biologics

ADMA Biologics is a fully integrated biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immune deficiency and infectious disease markets. The company produces three FDA-approved plasma-derived biologics: ASCENIV™ (for primary humoral immunodeficiency), BIVIGAM® (for primary immunodeficiency), and NABI-HB® (for hepatitis B immunity). ADMA also operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and collects plasma through its ADMA BioCenters subsidiary. In addition, ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumoniae, reflecting ongoing investment in pipeline expansion.

Forward-Looking Statements & Risks

This announcement contains forward-looking statements, including expectations for long-term growth, capital deployment, cash flow, and the completion and impact of the ASR and broader repurchase program. These plans are subject to various risks and uncertainties, including market conditions, regulatory factors, and the company’s financial performance. There is no guarantee that anticipated results will be achieved. Investors are encouraged to review ADMA’s filings with the SEC for a comprehensive discussion of potential risks.

Disclaimer: The information provided in this article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The article is based on company disclosures and contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those discussed.

View ADMA BIOLOGICS, INC. Historical chart here